<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fulvestrant: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fulvestrant: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fulvestrant: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8784" href="/d/html/8784.html" rel="external">see "Fulvestrant: Drug information"</a> and <a class="drug drug_patient" data-topicid="12502" href="/d/html/12502.html" rel="external">see "Fulvestrant: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F174701"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Faslodex</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867000"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Faslodex;</li>
<li>TEVA-Fulvestrant</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1015558"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Estrogen Receptor Antagonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F52812513"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6fa24ff6-6b9e-4de2-ab63-7ee1f07d553c">McCune-Albright syndrome; progressive precocious puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>McCune-Albright syndrome (MAS); progressive precocious puberty:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29292624']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29292624'])">Ref</a></span>): Female children 1 to 10 years: IM: 4 mg/kg once monthly; dosing based on a trial in 30 girls ≤10 years of age (range: 1 to 8.5 years) who received monthly injections for 1 year; significant decrease in vaginal bleeding and reduction in rates of skeletal maturation were reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22999294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22999294'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729729"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations available; based on experience in adult patients, renal elimination of fulvestrant is negligible.</p></div>
<div class="block dohp drugH1Div" id="F52729730"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations available; based on experience in adult patients, dosing adjustment is suggested.</p></div>
<div class="block doa drugH1Div" id="F174702"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8784" href="/d/html/8784.html" rel="external">see "Fulvestrant: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> In a dose comparison study, the once monthly fulvestrant maintenance dose was administered at 28 days ± 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24317176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24317176'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abd100a2-8b8b-4867-ade1-2a300a11f465">Breast cancer, advanced, monotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, advanced, monotherapy (postmenopausal patients; HR-positive): IM:</b> Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, advanced, monotherapy (postmenopausal patients; HR-positive, <i>HER2</i>-negative):</b>
<b>IM:</b> Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27908454']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27908454'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3feb95e9-891f-4a97-a57b-12d29ca2978a">Breast cancer, advanced or metastatic, combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, advanced or metastatic, combination therapy (postmenopausal patients; HR-positive, <i>HER2</i>-negative): Note:</b> A luteinizing hormone-releasing hormone (LHRH) agonist should be administered to pre-/perimenopausal patients receiving fulvestrant in combination with ribociclib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once every 28 days. Administer in combination with ribociclib; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29860922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29860922'])">Ref</a></span>).<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, advanced or metastatic, combination therapy (second-line endocrine-based combination therapy; pre- or postmenopausal patients, HR-positive, <i>HER2</i>-negative): Note:</b> An LHRH agonist should be administered to pre-/perimenopausal patients receiving fulvestrant in combination with abemaciclib or palbociclib (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IM:</b> Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once every 28 days. Administer in combination with palbociclib or abemaciclib; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28580882','lexi-content-ref-30345905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28580882','lexi-content-ref-30345905'])">Ref</a></span>).<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, advanced or metastatic, HR-positive, <i>HER2</i>-negative (off-label combinations):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>PIK3CA-</i>mutated<i>:</i> Males and postmenopausal patients: <b>IM:</b> Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once every 28 days (in combination with alpelisib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31091374','lexi-content-ref-33246021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31091374','lexi-content-ref-33246021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>PIK3CA, AKT1, </i>and/or<i> PTEN-</i>altered<i>:</i>
<b>Note:</b> For pre- and peri-menopausal patients, also administer an LHRH agonist (according to current clinical practice standards) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37256976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37256976'])">Ref</a></span>). For male patients, consider administering an LHRH agonist (according to current clinical practice standards) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Truqap.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Truqap.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IM:</b> Initial: 500 mg on days 1, 15, and 29; maintenance: 500 mg once every 28 days (in combination with capivasertib); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37256976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37256976'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c15d7614-96b8-4198-aacb-f5b808cc3a06">Breast cancer in male patients, advanced or metastatic, HR-positive, HER2-negative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer </b>
<b>in male patients, advanced or metastatic, HR-positive, HER2-negative (off-label use): </b>According to ASCO guidelines for management of male breast cancer, fulvestrant may be used in males with advanced or metastatic HR-positive, HER2-negative breast cancer; males who develop recurrent metastatic, HR-positive, HER2-negative breast cancer while receiving adjuvant endocrine therapy should be offered an alternative endocrine therapy; fulvestrant should not be used in visceral crisis or rapidly progressing disease. Endocrine therapy for males with advanced or metastatic, HR-positive, HER2-negative breast cancer may be sequenced as in females. Metastatic breast cancer in males is treated with the same endocrine therapy as in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>). <b>Note:</b> Other medications (abemaciclib, palbociclib, and ribociclib) have approval for use in combination with fulvestrant in male patients with advanced or metastatic breast cancer with disease progression.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991323"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, renal elimination of fulvestrant is negligible.</p></div>
<div class="block doha drugH1Div" id="F50988667"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Reduce initial and maintenance doses: Initial: 250 mg on days 1, 15, and 29; Maintenance: 250 mg once monthly.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (use has not been evaluated).</p></div>
<div class="block adr drugH1Div" id="F174672"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum glucose (18%), hot flash (7% to 11%), increased gamma-glutamyl transferase (49%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (13% to 16%), constipation (5% to 12%), decreased appetite (8% to 13%), diarrhea (6% to 25%), nausea (10% to 28%), stomatitis (10% to 13%), vomiting (6% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (4% to 40%; grade 3: ≤2%), lymphocytopenia (35%; grade 3: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (&gt;15%), increased serum alanine aminotransferase (5% to 37%), increased serum aspartate aminotransferase (5% to 48%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (25% to 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Pain at injection site (12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (8% to 32%), headache (8% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (8% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (5% to 15%), dyspnea (4% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (2% to 6%), pruritus (6% to 7%), skin rash (4% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum albumin (8%), decreased serum phosphate (8%), weight loss (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (6%), dysgeusia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukopenia (≤5%; grade 3: 1%; grade 4: 1%), neutropenia (2%; grade 3: 1%; grade 4: &lt;1%), thrombocytopenia (3%; grade 4: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (6% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (5% to 6%), back pain (8% to 9%), limb pain (6% to 7%), musculoskeletal pain (6%), myalgia (7%), ostealgia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Neuralgia, peripheral neuropathy, sciatica</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Venous thromboembolism</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatitis, increased serum bilirubin</p></div>
<div class="block coi drugH1Div" id="F174684"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to fulvestrant or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Pregnant or lactating patients.</p></div>
<div class="block war drugH1Div" id="F174670"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions, including urticaria and angioedema, have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection-site reactions: Events related to injection site, including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy, have been reported with fulvestrant administration. Due to the proximity of underlying sciatic nerve, use caution if administering at the dorsogluteal site.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from IM administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F174679"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Faslodex: 250 mg/5 mL (5 mL) [contains alcohol, usp, benzyl alcohol, benzyl benzoate, castor oil (ricine oil)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F174667"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323163"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Faslodex Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $232.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Fulvestrant Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg/5 mL (per mL): $18.00 - $218.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867001"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Faslodex: 250 mg/5 mL (5 mL) [contains alcohol, usp, benzyl alcohol, benzyl benzoate, castor oil (ricine oil)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg/5 mL (5 mL)</p></div>
<div class="block admp drugH1Div" id="F52612895"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For IM administration only; inject slowly over 1 to 2 minutes per injection; do not administer IV, SubQ, or intra-arterially. Pediatric patients may be able to receive entire dose as one injection; maximum dose volume in adults: 5 mL per injection per buttock.</p></div>
<div class="block adm drugH1Div" id="F174681"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM: <b>For IM administration only.</b> Administer 500 mg dose as two 5 mL IM injections (one in each buttocks [gluteal area]) slowly over 1 to 2 minutes per injection. If administering at the dorsogluteal site, use caution during injection due to the proximity of underlying sciatic nerve. Refer to facility policy for IM administration of large volumes.</p>
<p style="text-indent:-2em;margin-left:2em;">To prepare each syringe for administration, hold syringe upright; carefully tilt syringe cap back and forth (without twisting) until the cap disconnects for removal; pull cap off by pulling up without touching the syringe tip (to maintain sterility); attach safety needle to syringe tip and twist firmly to lock. Remove needle cap by pulling straight off to avoid damaging needle point, remove needle sheath and expel excess air from syringe prior to administration. Refer to product labeling for detailed instructions.</p></div>
<div class="block hazard drugH1Div" id="F49132598"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F174697"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Storage requirements may vary by product; also refer to manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Refrigerated storage only formulations: Store in original carton at 2°C to 8°C (36°F to 46°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Variable temperature storage formulations: May store refrigerated between 2°C to 8°C (36°F to 46°F) or at room temperature between 20°C to 25°C (68°C to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Do not freeze; store in original carton to protect from light.</p></div>
<div class="block usep drugH1Div" id="F53567038"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of hormone-receptor (HR)-positive advanced breast cancer (as monotherapy) in postmenopausal women with disease progression following endocrine therapy; treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (as monotherapy) in postmenopausal women not previously treated with endocrine therapy; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer (in combination with palbociclib or abemaciclib) in women with disease progression following endocrine therapy (All indications: FDA approved in adults); has also been used in treatment of McCune-Albright Syndrome (MAS) in girls associated with progressive precocious puberty</p></div>
<div class="block cyt drugH1Div" id="F174711"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F174674"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Fluoroestradiol F18: Estrogen Receptor Antagonists may diminish the diagnostic effect of Fluoroestradiol F18.  Management: Image patients with fluoroestradiol F-18 prior to starting systemic endocrine therapies that block the estrogen receptor. Use of fluoroestradiol F-18 should not delay indicated treatment.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49306794"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">For patients who could become pregnant, pregnancy testing is recommended within 7 days prior to initiation of fulvestrant and effective contraception should be used during treatment and for 1 year after the last fulvestrant dose.</p></div>
<div class="block pri drugH1Div" id="F174686"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Based on findings from animal reproduction studies and the mechanism of action, in utero exposure to fulvestrant may cause fetal harm.</p></div>
<div class="block mopp drugH1Div" id="F53567029"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">McCune-Albright syndrome: In the pediatric clinical trial (study duration: 12 months), the following were monitored: Serum estradiol, testosterone, LH, and FSH (baseline, and at 3, 6, 12 months of therapy); liver function test (baseline and at 12 months of therapy); CBC and INR at baseline; assessments of puberty status and growth at baseline and periodically during therapy (6 and 12 months: height, weight, Tanner stage, bone age [radiographs], vaginal bleeding data, and pelvic ultrasounds) (Sims 2012)</p></div>
<div class="block pha drugH1Div" id="F174669"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fulvestrant is an estrogen receptor antagonist; competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that causes a dose-related down-regulation of estrogen receptors and inhibits tumor growth.</p></div>
<div class="block phk drugH1Div" id="F174683"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration: IM: Steady state concentrations reached within first month, when administered with additional dose given 2 weeks following the initial dose; plasma levels maintained for at least 1 month</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~3 to 5 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99%; to plasma proteins (VLDL, LDL and HDL lipoprotein fractions)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via multiple biotransformation pathways (CYP3A4 substrate involved in oxidation pathway, although relative contribution to metabolism unknown); metabolites formed are either less active or have similar activity to parent compound</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1.7 to 8.5 years: 70.4 ± 8.1 days (Sims 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 250 mg: ~40 days</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (~90%); urine (&lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Children 1 to 8 years (based on a 4 mg/kg dose): Decreased by 32% compared to adults</p></div>
<div class="block phksp drugH1Div" id="F51192670"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In moderate hepatic impairment (Child-Pugh class B), the average AUC of fulvestrant increased by 70% compared with patients with normal hepatic function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539867"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alsel | Favesan | Full v | Kemflud | Trimicro</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Furetrant</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fulvenat</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Faslodex | Fuxran</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fazotikad</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Faslodex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-800.1">
<a name="800.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33246021">
<a name="33246021"></a>André F, Ciruelos EM, Juric D, et al. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. <i>Ann Oncol</i>. 2021;32(2):208-217. doi:10.1016/j.annonc.2020.11.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/33246021/pubmed" id="33246021" target="_blank">33246021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31091374">
<a name="31091374"></a>André F, Ciruelos E, Rubovszky G, et al; SOLAR-1 Study Group. Alpelisib for <i>PIK3CA</i>-mutated, hormone receptor-positive advanced breast cancer. <i>N Engl J Med</i>. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/31091374/pubmed" id="31091374" target="_blank">31091374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24317176">
<a name="24317176"></a>Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. <i>J Natl Cancer Inst</i>. 2014;106(1):djt337.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/24317176/pubmed" id="24317176" target="_blank">24317176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20855825">
<a name="20855825"></a>Di Leo A, Jerusalem G, Petruzelka L, et al, “Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer,” <i>J Clin Oncol</i>, 2010 28(30):4594-600.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/20855825/pubmed" id="20855825" target="_blank">20855825</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Faslodex (fulvestrant) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2021.</div>
</li>
<li>
<div class="reference">
                  Faslodex (fulvestrant) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; June 2020.</div>
</li>
<li>
<div class="reference">
                  Fulvestrant injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA LLC; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).<i> Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29292624">
<a name="29292624"></a>Neyman A, Eugster EA. Treatment of girls and boys with McCune-Albright syndrome with precocious puberty - update 2017. <i>Pediatr Endocrinol Rev</i>. 2017;15(2):136-141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/29292624/pubmed" id="29292624" target="_blank">29292624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27908454">
<a name="27908454"></a>Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. <i>Lancet</i>. 2016;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/27908454/pubmed" id="27908454" target="_blank">27908454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27217461">
<a name="27217461"></a>Rugo HS, Rumble RB, Macrae E, et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. <i>J Clin Oncol</i> 2016; 34(25):3069-3103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/27217461/pubmed" id="27217461" target="_blank">27217461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22999294">
<a name="22999294"></a>Sims EK, Garnett S, Guzman F, Paris F, Sultan C, Eugster EA; Fulvestrant McCune-Albright study group. Fulvestrant treatment of precocious puberty in girls with McCune-Albright syndrome. <i>Int J Pediatr Endocrinol. </i>2012;2012(1):26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/22999294/pubmed" id="22999294" target="_blank">22999294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29860922">
<a name="29860922"></a>Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 [published online June 3, 2018].<i> J Clin Oncol</i>. 2018; 36(24):2465-2472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/29860922/pubmed" id="29860922" target="_blank">29860922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28580882">
<a name="28580882"></a>Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. <i>J Clin Oncol.</i> 2017;35(25):2875-2884. doi: 10.1200/JCO.2017.73.7585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/28580882/pubmed" id="28580882" target="_blank">28580882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Truqap.1">
<a name="Truqap.1"></a>Truqap (capivasertib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37256976">
<a name="37256976"></a>Turner NC, Oliveira M, Howell SJ, et al; CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer.<i> N Engl J Med</i>. 2023;388(22):2058-2070. doi:10.1056/NEJMoa2214131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/37256976/pubmed" id="37256976" target="_blank">37256976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26030518">
<a name="26030518"></a>Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. <i>N Engl J Med</i>. 2015;373(3):209-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/26030518/pubmed" id="26030518" target="_blank">26030518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30345905">
<a name="30345905"></a>Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer.<i> N Engl J Med.</i> 2018;379(20):1926-1936. doi: 10.1056/NEJMoa1810527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/30345905/pubmed" id="30345905" target="_blank">30345905</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25519043">
<a name="25519043"></a>Zagouri F, Sergentanis TN, Chrysikos D, Dimopoulos MA, Psaltopoulou T. Fulvestrant and male breast cancer: a pooled analysis. <i>Breast Cancer Res Treat</i>. 2015;149(1):269-275. doi:10.1007/s10549-014-3240-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fulvestrant-pediatric-drug-information/abstract-text/25519043/pubmed" id="25519043" target="_blank">25519043</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 87808 Version 308.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
